Myriad Genetics Inc MYGN
We take great care to ensure that the data presented and summarized in this overview for MYRIAD GENETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MYGN
View all-
Black Rock Inc. New York, NY15.2MShares$150 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$105 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA6MShares$59.4 Million0.02% of portfolio
-
State Street Corp Boston, MA5.53MShares$54.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.35MShares$43 Million0.03% of portfolio
-
Glenview Capital Management, LLC New York, NY4.16MShares$41.2 Million1.44% of portfolio
-
Earnest Partners LLC Atlanta, GA3.97MShares$39.3 Million0.25% of portfolio
-
Camber Capital Management LP Boston, MA3.1MShares$30.7 Million0.98% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.77MShares$27.4 Million0.06% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN2.56MShares$25.3 Million0.76% of portfolio
Latest Institutional Activity in MYGN
Top Purchases
Top Sells
About MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Transactions at MYGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 15
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,764
-2.58%
|
$47,640
$10.07 P/Share
|
Mar 15
2025
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,335
-1.75%
|
$33,350
$10.07 P/Share
|
Mar 15
2025
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
1,572
-1.18%
|
$15,720
$10.07 P/Share
|
Mar 15
2025
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-1.38%
|
$6,840
$10.07 P/Share
|
Mar 15
2025
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,118
-2.9%
|
$301,180
$10.07 P/Share
|
Mar 15
2025
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,729
-0.94%
|
$37,290
$10.07 P/Share
|
Mar 14
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,544
-4.41%
|
$85,440
$10.07 P/Share
|
Mar 14
2025
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,390
-2.25%
|
$43,900
$10.07 P/Share
|
Mar 14
2025
|
Shereen Solaiman Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,060
-5.18%
|
$60,600
$10.07 P/Share
|
Mar 14
2025
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
3,417
-2.51%
|
$34,170
$10.07 P/Share
|
Mar 14
2025
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
855
-1.69%
|
$8,550
$10.07 P/Share
|
Mar 14
2025
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
37,564
-3.49%
|
$375,640
$10.07 P/Share
|
Mar 14
2025
|
Samraat S. Raha Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,649
-1.56%
|
$76,490
$10.07 P/Share
|
Mar 14
2025
|
Scott J. Leffler Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,217
-2.77%
|
$62,170
$10.07 P/Share
|
Mar 14
2025
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,847
-1.46%
|
$58,470
$10.07 P/Share
|
Mar 13
2025
|
Jennifer Lynne Fox Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,145
+33.58%
|
-
|
Mar 13
2025
|
Dale Muzzey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,773
+28.14%
|
-
|
Mar 13
2025
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,124
+21.69%
|
-
|
Mar 13
2025
|
Shereen Solaiman Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,145
+35.05%
|
-
|
Mar 13
2025
|
Margaret Ancona SVP, Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
54,124
+28.42%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.06M shares |
---|
Payment of exercise price or tax liability | 345K shares |
---|---|
Open market or private sale | 349K shares |